Found: 30
Select item for more details and to access through your institution.
Impact of atopic dermatitis lesion locations and extent on patient burden: A real‐world study.
- Published in:
- JEADV Clinical Practice, 2024, v. 3, n. 4, p. 1061, doi. 10.1002/jvc2.413
- By:
- Publication type:
- Article
Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.
- Published in:
- Science Signaling, 2018, v. 11, n. 555, p. 1, doi. 10.1126/scisignal.aaq1075
- By:
- Publication type:
- Article
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1145, doi. 10.1007/s13555-024-01158-4
- By:
- Publication type:
- Article
Anaphylactoid reaction to benzophenones, with recurrence during patch testing.
- Published in:
- Contact Dermatitis (01051873), 2019, v. 81, n. 4, p. 303, doi. 10.1111/cod.13293
- By:
- Publication type:
- Article
400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.023
- By:
- Publication type:
- Article
381 Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.009
- By:
- Publication type:
- Article
382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.010
- By:
- Publication type:
- Article
Contact Allergy to Topical Medicaments, Part 2: Steroids, Immunomodulators, and Anesthetics, Oh My!
- Published in:
- Cutis, 2022, v. 109, n. 1, p. 36
- By:
- Publication type:
- Article
Contact Allergy to Topical Medicaments, Part 1: A Double-edged Sword.
- Published in:
- Cutis, 2021, v. 108, n. 5, p. E52, doi. 10.12788/cutis.0390
- By:
- Publication type:
- Article
Plant Dermatitis: More Than Just Poison Ivy.
- Published in:
- Cutis, 2021, v. 108, n. 3, p. 124, doi. 10.12788/cutis.0340
- By:
- Publication type:
- Article
Update on Contact Dermatitis and Patch Testing in Patients With Skin of Color.
- Published in:
- Cutis, 2021, v. 108, n. 1, p. 10, doi. 10.12788/cutis.0292
- By:
- Publication type:
- Article
Acetophenone Azine: The 2021 American Contact Dermatitis Society Allergen of the Year.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Contact Dermatitis of the Hands: Is It Irritant or Allergic?
- Published in:
- Cutis, 2021, v. 107, n. 3, p. 129, doi. 10.12788/cutis.0204
- By:
- Publication type:
- Article
Contact Allergy to Nickel: Still #1 After All These Years.
- Published in:
- Cutis, 2021, v. 107, n. 1, p. 12, doi. 10.12788/cutis.0156
- By:
- Publication type:
- Article
Patch Testing 101, Part 2: After the Patch Test.
- Published in:
- Cutis, 2020, v. 106, n. 6, p. 292, doi. 10.12788/cutis.0138
- By:
- Publication type:
- Article
Patch Testing 101, Part 1: Performing the Test.
- Published in:
- Cutis, 2020, v. 106, n. 4, p. 165, doi. 10.12788/cutis.0093
- By:
- Publication type:
- Article
Tattoo Hypersensitivity Reactions: Inky Business.
- Published in:
- Cutis, 2020, v. 106, n. 2, p. 64, doi. 10.12788/cutis.0028
- By:
- Publication type:
- Article
Isobornyl Acrylate and Diabetic Devices Steal the Show for the 2020 American Contact Dermatitis Society Allergen of the Year.
- Published in:
- Cutis, 2020, v. 105, n. 6, p. 283, doi. 10.12788/cutis.0014
- By:
- Publication type:
- Article
Essential Oils Debunked: Separating Fact From Myth.
- Published in:
- Cutis, 2020, v. 105, n. 4, p. 174
- By:
- Publication type:
- Article
730 - Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.103
- By:
- Publication type:
- Article
726 - Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.099
- By:
- Publication type:
- Article
680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.054
- By:
- Publication type:
- Article
627 - A checklist to aid in identifying patients with atopic dermatitis who are candidates for systemic therapy.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.011
- By:
- Publication type:
- Article
626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.010
- By:
- Publication type:
- Article
622 - Shifting the care paradigm for individuals with skin of color (SOC): a comprehensive review of care gaps and emerging initiatives in dermatology.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.006
- By:
- Publication type:
- Article
594 - United States prevalence of atopic dermatitis in adults and pediatrics by race and ethnicity.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.002
- By:
- Publication type:
- Article
Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii20, doi. 10.1093/bjd/ljad498.024
- By:
- Publication type:
- Article
Conjunctivitis does not increase with longer duration of lebrikizumab exposure in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii5, doi. 10.1093/bjd/ljad498.007
- By:
- Publication type:
- Article
Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 3, p. 267, doi. 10.1001/jamadermatol.2022.5991
- By:
- Publication type:
- Article
Frequency of Contact Allergy to Implanted Cardiac Devices.
- Published in:
- 2019
- By:
- Publication type:
- journal article